An observational study in Hypertension, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-17.
Sponsored by Boehringer Ingelheim · Observational
To evaluate efficacy and tolerability of Micardis® / MicardisPlus® under usual daily-practice prescribing conditions with a special emphasis on controlling morning blood pressure
6,689 studies on the registry are indexed under Hypertension; 964 are open to participants now.
This study's enrollment of 13,248 is above the median of 210 across 1,358 observational studies indexed under Hypertension.
Browse Hypertension studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Outpatients with essential hypertension
Exclusion Criteria:
Drug: Telmisartan · Drug: Telmisartan in combination with hydrochlorothiazide
Changes in morning blood pressure (BP)
Time frame: Pre-dose, up to 6 months after start of treatment
Changes in metabolic laboratory parameters
Time frame: Pre-dose, up to 6 months after start of treatment
Changes in morning blood pressure in patients with or without telemonitoring (TM) of BP
Time frame: Pre-dose, up to 6 months after start of treatment
Investigator assessment of efficacy in reducing morning hypertension on a 5-point rating scale
Time frame: Up to 6 months after start of treatment
Investigator assessment of effects on metabolism on a 3-point rating scale
Time frame: Up to 6 months after start of treatment
Investigator assessment of tolerability on a 5-point rating scale
Time frame: Up to 6 months after start of treatment
Number of patients with adverse events
Time frame: Up to 6 months
Changes in morning heart rate
Time frame: Pre-dose, up to 6 months after start of treatment
No study locations are listed for this record.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim